SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, is hosting a virtual KOL event titled “Metabolic Rewiring with CB1 Inhibition” today at 9:00 AM ET.

圣地亚哥，2024年7月24日（环球通讯社）--Skye Bioscience，Inc.（纳斯达克：Skye）（“Skye”）是一家临床阶段的生物制药公司，专注于为代谢健康开辟新的治疗途径，今天上午9:00举办了一场名为“CB1抑制代谢重新连接”的虚拟KOL活动。

During this event the company and members of its clinical advisory board will discuss the scientific rationale for its Nimacimab peripheral CB1 inhibitor and the CBeyond™ Phase 2 clinical trial design, as well as a collaboration with Beacon Biosignals to evaluate sleep quality and sleep apnea in the Phase 2 trial.

在此次活动中，该公司及其临床咨询委员会成员将讨论其尼莫单抗外周CB1抑制剂和CBeyond™2期临床试验设计的科学依据，以及与Beacon Biosignals合作评估2期试验中的睡眠质量和睡眠呼吸暂停。

Advanced registration is required to participate in the webcast and can be completed by clicking here. The presentation and a replay of the call will also be available on the Company’s website. The event will feature distinguished obesity key opinion leaders combined with Skye’s management team. The KOL event will cover the following topics: Current treatment landscape for obesityMechanism and potential role of peripheral CB1 inhibition as a differentiated and complementary anti-obesity therapeutic pathway to other mechanisms of actionPreclinical and Phase 1 clinical data on NimacimabFinalized CBeyond™ Phase 2 clinical trial goals and designIntroduction of collaboration to assess sleep disturbances in Phase 2 Nimacimab studyOverview of Nimacimab clinical development planQ&A session.

参加网络广播需要高级注册，点击此处即可完成。该演示文稿和电话重播也将在该公司的网站上提供。此次活动将有杰出的肥胖关键意见领袖和Skye的管理团队共同参与。KOL活动将涵盖以下主题：肥胖机制的当前治疗前景以及外周CB1抑制作为其他作用机制的分化和互补的抗肥胖治疗途径的潜在作用尼莫单抗的临床前和1期临床数据最终确定了CBeyond™2期临床试验目标和设计在尼莫单抗2期研究中评估睡眠障碍的合作介绍尼莫单抗临床开发计划Q＆a会议概述。

“We believe there is a promising opportunity for our peripheral CB1 inhibitor, Nimacimab, to play a distinct and complementary role compared to currently available treatments for weight loss, including GLP-1 receptor agonists,” said Tu Diep, Chief Development Officer of Skye. “The KOLs bring extensive experience and a unique perspective in the rapidly evolving field of obesity, and .

Skye首席开发官Tu Diep说：“我们认为，与目前可用的减肥治疗方法（包括GLP-1受体激动剂）相比，我们的外周CB1抑制剂尼马单抗有希望发挥独特和互补的作用。”。“KOL在迅速发展的肥胖领域带来了丰富的经验和独特的视角。